PT - JOURNAL ARTICLE AU - Ye Zhou AU - Leiyu Chen AU - Tianshu Jiang AU - Liangfeng Fan AU - Hang Lei AU - Yuqing Wang AU - Hasiyati Heililahong AU - Jianqing Mi AU - Danxin Du AU - Tianhong Miao AU - Rong Xia AU - Xuefeng Wang AU - Dong Xiang AU - Xiaohong Cai AU - Xiaofeng Tang TI - 2-mercaptoethanol (2-ME)-based IATs or polybrene method mitigates the interference of anti-CD38 immunotherapy on blood compatibility tests AID - 10.1101/2020.12.14.20238311 DP - 2020 Jan 01 TA - medRxiv PG - 2020.12.14.20238311 4099 - http://medrxiv.org/content/early/2020/12/17/2020.12.14.20238311.short 4100 - http://medrxiv.org/content/early/2020/12/17/2020.12.14.20238311.full AB - Background Treating red blood cells (RBCs) with dithiothreitol (DTT) is a wildly-recommended to overcome the interference of anti-CD38 immunotherapy with blood compatibility testing. Nevertheless, DTT can be hard to obtain in clinical laboratory, while its use in routine practice may be time-consuming. In the following study, we explored the feasibility of using a commercial 2-mercaptoethanol (2-ME) working solution or the time-saving polybrene method to mitigate the daratumumab (DARA) interference.Materials and Methods Antibody screening and cross-matching were performed using 2-ME or DTT-based indirect antiglobulin tests (IATs) and polybrene method (human IgG anti-E same IATs titer as DARA as positive control) on 37 samples, and these samples were from patients enrolled in the “Several methods resolve the interference of anti-CD38 monoclonal antibody on blood compatibility tests” clinical trial (www.chictr.org.cn identifier: ChiCTR2000040761). Most clinically important blood group antigens on RBCs were detected after treatment with 2-ME or DTT. Hemoglobin values were compared after 69 units RBCs were transfused with compatible cross-matching results by a 2-ME-based method or polybrene test.Results Treating RBCs with 2-ME eliminates the DARA interference with the antibody screening or cross-matching; yet, K antigen is denatured during treatment. DARA with 2+ agglutinations of anti-E control does not interfere with antibody screening and cross-matching via polybrene method. After RBCs transfusion with a negative cross-matching test by 2-ME-based IATs or polybrene method, hemoglobin significantly increased without adverse transfusion reactions.Conclusion 2-ME-based IATs or polybrene method could be used to mitigate DARA interference as DTT.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialChiCTR2000040761 (http://www.chictr.org.cn)Funding StatementThis work was supported by WeiGao Science Foundation of Chinese Society of Blood Transfusion (CSBT-WG-2019-01), and National Natural Science Foundation of China (82000183).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by all 5 ethics committees of the participated institutions; they are the ethics committee of Changzheng Hospital, the ethics committee of Shanghai Blood Center, the ethics committee of Ruijin Hospital, the ethics committee of Huashan Hospital, the ethics committee of Beijing Red Cross Blood Center. Written informed consent was obtained for each patient.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used to support the findings of this study are available from the corresponding author upon request